Corbus Pharmaceuticals Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $881,705 |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$39.8M | -$56.0M |
| Operating expenses | $85.3M | $48.7M | $45.1M | $39.8M | $56.9M |
| Cash from operations | -$64.5M | -$41.8M | -$36.1M | -$37.5M | -$48.2M |
| Capital expenditure | $7,000 | $0 | $0 | $13,449 | $54,172 |
| Free cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.6M | -$48.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $168.2M | $155.9M | $28.3M | $66.3M | $107.7M |
| Total liabilities | $20.7M | $13.5M | $35.2M | $33.3M | $38.6M |
| Total debt | — | $0 | $15.9M | $18.8M | $18.7M |
Shares outstanding 18.5M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.